SLRX vs VICI · $4.9M cap vs P/E 9.3, rev $3.85B
Salarius Pharmaceuticals Inc (SLRX) versus VICI Properties Inc (VICI) — a side-by-side from cached financials, not a winner call.
Salarius Pharmaceuticals Inc (SLRX) is a biotechnology company listed on NASDAQ.
VICI Properties Inc (VICI) is a reit - diversified company listed on NYSE.
Latest reported SLRX revenue for 2023-03-31 was $0. Net income was -$5.3M. SLRX currently screens at market cap $4.9M.
Latest reported VICI revenue for 2024-12-31 was $3.85B. Net income was $2.72B. Revenue was up 6.6% from 2023-12-31 to 2024-12-31. VICI currently screens at market cap $29.32B and trailing P/E 9.3.
SLRX currently screens at market cap $4.9M. VICI currently screens at market cap $29.32B and trailing P/E 9.3.
Not investment advice. Open the SLRX and VICI stock pages for the full models.
Not investment advice.